City Of Hope
Time to vote: Healio | HemOnc Today announce 2025 Disruptive Innovators nominees
Healio | HemOnc Today is excited to announce the nominees for its annual Disruptive Innovators Awards in oncology and hematology.
Mushroom supplement may slow prostate cancer progression
White button mushrooms promoted antitumor activity among men with prostate cancer, according to results of an ongoing randomized phase 2 trial.
Healio seeks nominees for Disruptive Innovators in oncology/hematology
Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.
‘All for one’: City of Hope oncologist focuses on patients after evacuating fires
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when his wife looked in the backyard and saw a “huge red glow.”
Oncologists: Surgeon General’s 'bold statement' elevates conversation about alcohol, cancer
U.S. Surgeon General Vivek Murthy, MD, MBA, issued an advisory today that includes several recommendations designed to reduce the impact of alcohol on cancer incidence and mortality.
Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL
SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.
Higher fiber intake improves survival, reduces GVHD after HSCT
SAN DIEGO — Increased fiber intake after allogeneic hematopoietic stem cell transplantation appeared linked to improved outcomes, according to study results presented at ASH Annual Meeting and Exposition.
From 300 patients to 1,600, City of Hope remains at the forefront of cell therapy
When Healio | Cell Therapy Next visited City of Hope in 2019, the institute boasted a robust cell therapy program, having treated 300 patients with the then-newly approved therapy.
Timing of immunotherapy influences benefit in limited-stage small cell lung cancer
Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.
Nivolumab regimen halves risk for progression, death in Hodgkin lymphoma
Nivolumab plus chemotherapy significantly extended PFS for children and adults with newly diagnosed advanced Hodgkin lymphoma compared with standard of care, according to results of a randomized phase 3 trial.